Pfizer Announces Availability of XELJANZ®▼ (tofacitinib citrate) Prolonged-Release Tablets for Rheumatoid Arthritis

XELJANZ 11mg prolonged-release tablets provide RA patients a once-daily dosing option

Pfizer Healthcare Ireland has today announced the availability of XELJANZ® (tofacitinib citrate) 11mg prolonged-release tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate in patients who have had an inadequate response or intolerance to methotrexate or other DMARDs.